Rekah Pharmaceutical Prod (XTAE:REKA) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


XTAE:REKA Rekah Pharmaceutical Prod Ltd XTAE:REKA
57 GF Score
Price ₪10.62
GF Value ₪13.05
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Rekah Pharmaceutical Prod Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Rekah Pharmaceutical Prod's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XTAE:REKA vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rekah Pharmaceutical Prod Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Rekah Pharmaceutical Prod's Margin of Safety % (DCF Earnings Based) falls into.


XTAE:REKA
57GF Score
Rekah Pharmaceutical Prod Ltd XTAE:REKA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?

Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued. The current stock price of ₪10.62 is trading 18.6% below its estimated GF Value™ of ₪13.05. GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.

Key valuation signals for XTAE:REKA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₪13.05 vs. price of ₪10.62 (18.6% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rekah Pharmaceutical Prod Business Description

Address 30 Hamelacha Street, Holon, ISR
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score

Get the complete analysis for XTAE:REKA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪10.62
Price
₪13.05
GF Value